DGAP-News: STRATEC publishes preliminary figures for the 2015 financial year and adjusts financial forecast


DGAP-News: STRATEC Biomedical AG / Key word(s): Preliminary Results/Change
in Forecast
STRATEC publishes preliminary figures for the 2015 financial year and
adjusts financial forecast

15.03.2016 / 23:50
The issuer is solely responsible for the content of this announcement.

---------------------------------------------------------------------------

STRATEC publishes preliminary figures for the 2015 financial year and
adjusts financial forecast

- Sales increased to EUR 146.9 million in 2015 financial year
  (previous year: EUR 144.9 million)
- EBIT margin improved to 18.3% (previous year: 16.6%)
  (Sales and EBIT margin are preliminary, unaudited results for FY 2015)
- Increase in dividend to EUR 0.75 per share (previous year: EUR 0.70) to
  be proposed
- 2016 sales forecast of between EUR 150 million and EUR 154 million
- 2016 EBIT margin should remain stable
- Mid-term financial forecast for 2014 to 2017: average annual sales
  growth (CAGR)of around 6%

Birkenfeld, March 15, 2016

STRATEC Biomedical AG, Birkenfeld, Germany (Frankfurt: SBS; Prime Standard,
TecDAX), today published (by way of an ad-hoc announcement) an adjustment
in its financial forecast up to and including 2017 and its preliminary,
unaudited figures for the 2015 financial year.

Preliminary figures for 2015 and proposed dividend
Based on preliminary, unaudited figures, STRATEC Biomedical AG increased
its sales by 1.8% to EUR 146.9 million in the 2015 financial year. The EBIT
margin rose significantly from 16.6% in the previous year to 18.3%. The
final audited results for the 2015 financial year will be published on
April 14, 2016.

At the meeting to be held to adopt the financial statements, the Board of
Management and Supervisory Board will discuss submitting a proposed
dividend of EUR 0.75 per share for the 2015 financial year for approval by
the Annual General Meeting. Following a dividend payment of EUR 0.70 per
share in the previous year, this would represent an increase by 7.1%. This
would reflect the company's consistently strong earnings performance and
its ongoing positive business prospects, also in respect of potential
company acquisitions.

Adjustment to sales forecast
For the current 2016 financial year, STRATEC now expects its sales to grow
to between EUR 150 million and EUR 154 million. This means, however, that
the company will not achieve its mid-term financial forecast issued in
2013, which was valid to date and provided for average annual sales growth
(CAGR) of 8% to 12% in the years from 2014 to 2017. The new target for
average sales growth between 2014 and 2017 now amounts to around 6%.

Growth held back by weak business in China
The adjustment in the mid-term outlook is largely due to the forecast and
order reductions received from a major customer that is one of the world's
top three in-vitro diagnostics players and that previously generated a
large share of its STRATEC product sales in China. Other customers have
also corrected their call-up expectations, here too with reference to the
more difficult economic climate, especially in Asia. Furthermore, some of
STRATEC's development projects will only generate the sales contributions
originally budgeted for 2016 and 2017 at a later date. This is due to
delays in the availability of comprehensive test menus and in approval
procedures.

Given these delays and in view of a very weak first quarter, 2016 sales are
unlikely to meet market expectations, even if other projects show
unexpected upside developments. The EBIT margin, which due to the product
mix has recently risen faster than previously budgeted, should be
maintained in 2016 at around the level attained in 2015.

About STRATEC
STRATEC Biomedical AG (www.stratec.com) designs and manufactures fully
automated analyzer systems for its partners in the fields of clinical
diagnostics and biotechnology. These partners market such systems, in
general together with their own reagents, as system solutions to
laboratories, blood banks and research institutes around the world. The
company develops its products on the basis of its own patented
technologies.

Shares in the company (ISIN: DE000STRA555) are traded in the Prime Standard
segment of the Frankfurt Stock Exchange and are listed in the TecDAX select
index of the German Stock Exchange.

Further information can be obtained from:
STRATEC Biomedical AG
André Loy, Corporate Communications
Gewerbestr. 37, 75217 Birkenfeld
Germany
Tel: +49 7082 7916-190
Fax: +49 7082 7916-999
ir@stratec.com
www.stratec.com


---------------------------------------------------------------------------

15.03.2016 Dissemination of a Corporate News, transmitted by DGAP - a
service of EQS Group AG.
The issuer is solely responsible for the content of this announcement.

The DGAP Distribution Services include Regulatory Announcements,
Financial/Corporate News and Press Releases.
Media archive at www.dgap-medientreff.de and www.dgap.de

---------------------------------------------------------------------------


   Language:    English                                                     
   Company:     STRATEC Biomedical AG                                       
                Gewerbestr. 37                                              
                75217 Birkenfeld                                            
                Germany                                                     
   Phone:       +49 (0)7082 7916 0                                          
   Fax:         +49 (0)7082 7916 999                                        
   E-mail:      info@stratec.com                                            
   Internet:    www.stratec.com                                             
   ISIN:        DE000STRA555                                                
   WKN:         STRA55                                                      
   Indices:     TecDAX                                                      
   Listed:      Regulated Market in Frankfurt (Prime Standard); Regulated   
                Unofficial Market in Berlin, Dusseldorf, Hamburg, Hanover,  
                Munich, Stuttgart, Tradegate Exchange; Terminbörse EUREX    
 
 
   End of News    DGAP News Service  
---------------------------------------------------------------------------

445561 15.03.2016